TLDR Samsara (IOT) jumped 15% on Friday after Q4 adjusted EPS of $0.18 beat the $0.13 consensus by $0.05 Revenue came in at $444.3M, up 28% year-over-year, toppingTLDR Samsara (IOT) jumped 15% on Friday after Q4 adjusted EPS of $0.18 beat the $0.13 consensus by $0.05 Revenue came in at $444.3M, up 28% year-over-year, topping

Samsara (IOT) Stock Surges 15% After Blowing Past Q4 Earnings Estimates

2026/03/06 23:42
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Samsara (IOT) jumped 15% on Friday after Q4 adjusted EPS of $0.18 beat the $0.13 consensus by $0.05
  • Revenue came in at $444.3M, up 28% year-over-year, topping estimates of $422.3M
  • Annual recurring revenue hit $1.9B, up roughly 30% year-over-year
  • FY2027 EPS guidance of $0.65–$0.69 came in well above analyst expectations of ~$0.33
  • Multiple analysts reiterated Buy/Outperform ratings, with price targets ranging from $39 to $44

Samsara (IOT) posted a strong fiscal Q4 on Thursday, and Wall Street wasted no time reacting. The stock jumped 15% on Friday to $34.10, giving back some of the 17% drop it had suffered year-to-date heading into the print.

The numbers were hard to argue with. Revenue hit $444.3 million for the quarter, up 28.3% from the same period a year ago and well ahead of the $422.3 million analysts had penciled in. Adjusted EPS came in at $0.18, beating the $0.13 consensus by five cents.


IOT Stock Card
Samsara Inc., IOT

The company closed the year with $1.9 billion in annual recurring revenue, up 30% year-over-year — a key metric for a company still leaning into its growth story.

Guidance Turns Heads

The guidance may have been just as important as the beat. Samsara set its FY2027 EPS range at $0.65–$0.69. That compares to a street consensus sitting around $0.33 — more than double what analysts had modeled. Q1 2027 EPS guidance came in at $0.12–$0.13, also above expectations.

Management outlined a 21%–22% revenue growth target for FY2027 and continued to push its AI expansion story.

Evercore ISI analyst Kirk Materne reiterated an Outperform rating and named Samsara a “top idea,” replacing Oracle on that list. He pointed to vertical integration as a buffer against AI disruption — an argument that carried weight given how hard other software stocks have been hit on that concern.

BTIG analyst Nick Altmann kept his Buy rating but trimmed his price target from $55 to $45 to reflect lower industry-wide valuations. He flagged Samsara’s proprietary dataset as an advantage in building out AI features.

Analyst Price Targets

BMO Capital Markets raised its target from $40 to $44 with an Outperform rating. Piper Sandler lifted its target to $39 from $37 and kept an Overweight rating, implying about 22.8% upside from the prior close. KeyCorp moved its target up to $41 from $40 with an Overweight rating.

Royal Bank of Canada has a $35 target on the stock.

The consensus rating across 17 analysts sits at “Moderate Buy” with an average price target of $45.69. One analyst has a Strong Buy, eleven have Buy, four have Hold, and one has Sell.

Samsara’s 52-week range runs from $23.38 to $48.40. The stock carries a market cap of roughly $18.3 billion.

One note that could temper enthusiasm: insiders have been active sellers. Founders John Bicket and Sanjit Biswas each sold 263,900 shares on January 6 at $34.40 per share — roughly $9 million each. Over the past 90 days, insiders sold approximately 2.9 million shares valued at $92 million total. Corporate insiders still hold about 46.5% of the company.

Institutional ownership stands at 96%, with several funds adding to positions in recent quarters.

Samsara’s 50-day moving average sits at $30.39, and the stock’s Friday close of $34.10 puts it back above that level.

The post Samsara (IOT) Stock Surges 15% After Blowing Past Q4 Earnings Estimates appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09